Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)]:
SEC Accession No. 0001437749-17-009351
Filing Date
2017-05-16
Accepted
2017-05-16 09:11:47
Documents
2
Effectiveness Date
2017-05-16

Document Format Files

Seq Description Document Type Size
1 FORM POS EX atrn20170515_posex.htm POS EX 51920
2 EXHIBIT 5.1 ex5-1.htm EX-5.1 21484
  Complete submission text file 0001437749-17-009351.txt   74701
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: POS EX | Act: 33 | File No.: 333-217963 | Film No.: 17847259
SIC: 7389 Services-Business Services, NEC